146 related articles for article (PubMed ID: 33435341)
1. Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.
Lachaine J; Beauchemin C; Guinan K; Thebault P; Aw A; Banerji V; Fleury I; Owen C
Curr Oncol; 2021 Jan; 28(1):332-345. PubMed ID: 33435341
[No Abstract] [Full Text] [Related]
2. Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.
Lachaine J; Guinan K; Aw A; Banerji V; Fleury I; Owen C
Curr Oncol; 2023 Apr; 30(5):4483-4498. PubMed ID: 37232797
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
[TBL] [Abstract][Full Text] [Related]
4. Cost-minimisation analysis of chronic lymphocytic leukemia in Spain in the era of oral targeted therapies.
Montañés B; Casado G; Medina Á; Nieto P; Ramírez-Payer Á
Farm Hosp; 2022 Jan; 46(2):72-79. PubMed ID: 35379098
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.
Leslie LA; Gangan N; Tan H; Huang Q
Curr Med Res Opin; 2022 Dec; 38(12):2149-2161. PubMed ID: 36205521
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents.
Waweru C; Kaur S; Sharma S; Mishra N
Curr Med Res Opin; 2020 Sep; 36(9):1481-1495. PubMed ID: 32634056
[TBL] [Abstract][Full Text] [Related]
8. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
10. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
[TBL] [Abstract][Full Text] [Related]
12. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
13. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
14. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
15. Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.
Cuneo A; Cavazzini F; Cavallari M; Foà R; Rigolin GM
Cancer J; 2021 Jul-Aug 01; 27(4):320-327. PubMed ID: 34398559
[TBL] [Abstract][Full Text] [Related]
16. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
17. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
18. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
Rozovski U; Keating MJ; Estrov Z
Acta Haematol; 2018; 140(1):51-54. PubMed ID: 30114695
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
[TBL] [Abstract][Full Text] [Related]
20. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]